CG Oncology, Inc.'s promising bladder cancer therapy has strong clinical results, competitive CR rates, and a $69 target ...

CG Oncology (NASDAQ:CGON – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright ...

CG Oncology, Inc. reported net losses of $88.0 million and $48.6 million for the years ended December 31, 2024, and 2023, ...

Marker Therapeutics is advancing a unique multi antigen recognizing (MAR)-T cell therapy platform designed to target multiple tumor-associated antigens simultaneously, an approach that has shown ...

A precision medicine workflow integrating proteomics and personalized xenograft models was developed and applied to an ...

The Investec Champions Cup returns with the last-16 on Friday and BBC Sport explores five things to look out for across the weekend.

Tarsus Pharmaceuticals Inc. (Nasdaq: TARS), ranked No. 1 in the midsize category, has become a standout in OC’s biotech ...

Before Fadel Lawandy joined Chapman University, where he is the director of the C. Larry Hoag Center for Real Estate and Finance and director of the Janes Financial Center, he was a portfolio manager ...

The average of price targets set by Wall Street analysts indicates a potential upside of 157.9% in CG Oncology, Inc. (CGON). While the effectiveness of this highly sought-after metric is questionable, ...

In a report released today, Sean Laaman from Morgan Stanley maintained a Buy rating on CG Oncology, Inc. (CGON – Research Report), with a price ...

Durability Results from BOND-003 data will be presented as a late breaker as part of AUA’s Practice-changing, Paradigm-shifting Clinical Trials in Urology - ...

Durability Results from BOND-003 data will be presented as a late breaker as part of AUA’s Practice-changing, Paradigm-shifting Clinical Trials in Urology - - Additional updates from across CG ...